AbbVie Inc. expects to increase its cost sharing assistance for Humira (adalimumab) patients going forward as a result of the expanded use of commercial insurance policies designed to undercut the value of copay coupons, according to Chairman and CEO Richard Gonzalez.
Copay accumulator programs, which are becoming more widely used by payers, block the financial assistance provided by manufacturers from being...





